Diagnostic delay of myositis: an integrated systematic review

Tergel Namsrai, Anne Parkinson, Anita Chalmers, Christine Lowe, Matthew Cook, Christine Phillips, Jane Desborough*

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    14 Citations (Scopus)

    Abstract

    Background: Idiopathic inflammatory myopathies (IIM) are a heterogenous group of rare muscular autoimmune diseases characterised by skeletal muscle inflammation with possible diagnostic delay. Our aim was to review the existing evidence to identify overall diagnostic delay for IIM, factors associated with diagnostic delay, and people’s experiences of diagnostic delay. Methods: Three databases and grey literature sources were searched. Diagnostic delay was defined as the period between the onset of symptoms and the year of first diagnosis of IIM. We pooled the mean delay using random effects inverse variance meta-analysis and performed subgroup analyses. Results: 328 titles were identified from which 27 studies were included. Overall mean diagnostic delay was 27.91 months (95% CI 15.03–40.79, I2 = 99%). Subgroup analyses revealed a difference in diagnostic delay between non-inclusion body myositis (IBM) and IBM types. There was no difference in diagnostic delay between studies in which myositis specific autoantibodies (MSA) were tested or not tested. In countries with gatekeeper health systems, where primary care clinicians authorize access to specialty care, people experienced longer periods of diagnostic delay than people with IIM in countries with non-gatekeeper systems. While studies discussed factors that may influence diagnostic delay, significant associations were not identified. No qualitative studies examining people’s experiences of diagnostic delay were identified. Conclusion: Diagnostic delay of IIM has extensive impacts on the quality of life of people living with this disease. Understanding the experiences of people with IIM, from symptom onset to diagnosis, and factors that influence diagnostic delay is critical to inform clinical practice and training activities aimed at increasing awareness of this rare disease and expediting diagnosis. Trial registration: PROSPERO Registration number: CRD42022307236 URL of the PROSPERO registration: https://www.crd.york.ac.uk/PROSPEROFILES/307236_PROTOCOL_20220127.pdf

    Original languageEnglish
    Article number420
    JournalOrphanet Journal of Rare Diseases
    Volume17
    Issue number1
    DOIs
    Publication statusPublished - Dec 2022

    Fingerprint

    Dive into the research topics of 'Diagnostic delay of myositis: an integrated systematic review'. Together they form a unique fingerprint.

    Cite this